Table 2.
Studies evaluating irAEs after ICI rechallenge with concurrent IST
| Study | Cancer type | ICI(s) | irAE-1 | Patients rechallenged with IST | IST, n (%) | irAE-2, n (%) | Recurrent irAE, n (%) | New irAE, n (%) | Recurrent irAE grade ≥3, n (%) | Discontinuation ratea | ORR | DCR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kim et al. | Melanoma | anti-PD-1 → anti-CTLA-4 | Arthritis | 1 | Tocilizumab | NR | 0 (0) | NA | NA | NA | NR | NR |
| Abu-Sbeih et al. | Mixed | 47 anti-CTLA-4; 79 anti-PD-(L)1; 41 ICI combination | Colitis | 113 | Corticosteroid, 113 (100) Infliximab or Vedolizumab, 24 (14) | NR | 47 (42) | NR | NR | NR | NR | NR |
| Badran et al. | Mixed | 1 anti-CTLA-4; 2 anti-PD-1; 2 anti-CTLA-4 + anti-PD-1 | Colitis | 5 | Infliximab, 5 (100) | 3 (60) | 1 (20) | 2 (40) | 2 (40) | 1/5 (20) | 20% | 80% |
DCR, disease control rate; ICI, immune checkpoint inhibitor; irAEs, immune-related adverse events; irAE-1, irAE before rechallenge; irAE-2, irAE after rechallenge; IST, immunosuppressive therapy; NA, not applicable; NR, not reported; ORR, overall response rate
aDiscontinuation rate due to toxicity